Pharmacodynamic and tolerability studies of candidate ad drugs in a transgenic ad mouse model
Ended Purchase Order Awarded Last action
- Contract number
- 75N95023P00617
- Awardee
-
Scantox Neuro GMBH UEI ED41XCPBEPU1
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $249,334
Award facts
- Opportunity
-
- SOURCES SOUGHT: Pharmacodynamic and Tolerability studies of candidate AD drugs in a transgenic AD mouse model Pre-Solicitation · 75N95023Q00447 · Posted Jul 3, 2023
- Contract value 100% obligated
- $249,334.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute on Aging National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Austria
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Vendor DUNS or Name Change - Non-Novation | $0 | |
| Original award | $249,334 |
About this award
This is a $249,334 firm fixed-price purchase order awarded by the National Institute on Aging (NIA) to Scantox Neuro GMBH, a for-profit organization based in Austria. The contract supports pharmacodynamic and tolerability studies of candidate Alzheimer's disease (AD) drugs using a transgenic AD mouse model. This work builds on NIA's ongoing efforts under the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) and Experimental Validation of Candidate Alzheimer's Disease Treatments Identified by Multi-Omics Analyses (PREVENT-AD) studies to identify and validate potential disease-modifying AD treatments, including through drug repurposing strategies. The contract has no small business set-aside designation. Scantox Neuro GMBH has previously received over $1.37 million in NIA contracts related to AD research, and was recently awarded a $2.3 million indefinite delivery contract to support further experimental validation of candidate AD treatments.
Quick answers
Who was awarded contract 75N95023P00617?
75N95023P00617 was awarded to Scantox Neuro GMBH by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2023.
How much is contract 75N95023P00617 worth?
The government has obligated $249,334 on 75N95023P00617.
Which agency awarded contract 75N95023P00617?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95023P00617, with funding from National Institute on Aging (National Institutes of Health).
Was contract 75N95023P00617 competed?
The extent of competition for 75N95023P00617 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award